Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions
American Journal of Clinical Dermatology · 2026-05 · 27 (3) · 587-609
DOI: 10.1007/s40257-026-01010-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Dermatology, online erschienen am 09.04.2026. Verfasst von Connie R Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Skin Diseases. Die Arbeit nennt 172 Literaturangaben. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Cutaneous graft-versus-host disease (GVHD) is a frequent manifestation after allogeneic hematopoietic stem cell transplantation. This review synthesizes classification, pathophysiology, risk factors, and diagnostic frameworks for acute and chronic cutaneous GVHD. Acute cutaneous GVHD typically presents as a morbilliform eruption, with severe cases presenting with bullae and full-thickness desquamation. Chronic cutaneous GVHD presents in more protean ways, including both nonsclerotic and sclerotic phenotypes. We review current diagnostic criteria, staging, clinical and histopathologic features, and differential diagnoses of acute and chronic cutaneous GVHD. Additionally, we summarize management across the disease continuum, including skin-directed therapy, systemic therapy, and approved therapies for steroid-refractory GVHD such as ruxolitinib and remestemcel-L for acute GVHD and ibrutinib, ruxolitinib, belumosudil, and axatilimab for chronic GVHD. We also discuss emerging therapeutic strategies and areas of active investigation in GVHD therapeutics. However, despite therapeutic advances for chronic GVHD (cGVHD), nonresponse and relapse remain common. Early dermatologic involvement to diagnose, classify, and participate in multidisciplinary management is critical to improving outcomes for patients experiencing cutaneous GVHD. Biomarker-informed risk stratification and treatment selection, mechanistically informed combination regimens, and steroid-sparing first-line approaches for GVHD treatment are research priorities to enhance efficacy while minimizing toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
- Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
- Carle Illinois College of Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA.
- Harvard Medical School, Boston, MA, USA.
- Division of Dermatology, City of Hope, Duarte, CA, USA.
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Shi, C. R., Patil, M. K., Riew, G. J., Modi, B., Markova, A., Cowen, E. W., & Baumrin, E. (2026). Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions. American Journal of Clinical Dermatology, 27(3), 587-609. https://doi.org/10.1007/s40257-026-01010-9
Vancouver
Shi CR, Patil MK, Riew GJ, Modi B, Markova A, Cowen EW, et al. Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions. American Journal of Clinical Dermatology. 2026;27(3):587-609. doi:10.1007/s40257-026-01010-9
BibTeX
@article{Shi2026,
author = {Shi, Connie R and Patil, Mihir K and Riew, Grant J and Modi, Badri and Markova, Alina and Cowen, Edward W and Baumrin, Emily},
title = {Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions},
journal = {American Journal of Clinical Dermatology},
year = {2026},
volume = {27},
number = {3},
pages = {587--609},
doi = {10.1007/s40257-026-01010-9}
}
EUVIMED